BRISBANE, Australia, September 20, 2007- Progen Pharmaceuticals Limited (ASX: PGL; NASDAQ: PGLA) today announced that the Commission of the European Communities has granted orphan product designation for PI-88 for the treatment of hepatocellular carcinoma, or primary liver cancer. This follows the positive recommendation received in August, from the European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Orphan Medical Products for PI-88 in this indication.
